resmetirom
Selected indexed studies
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. (N Engl J Med, 2024) [PMID:38324483]
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. (Nat Med, 2023) [PMID:37845512]
- Resmetirom: First Approval. (Drugs, 2024) [PMID:38771485]
_Worker-drafted node — pending editorial review._
Connections
resmetirom is a side effect of
Sources
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. (2024) pubmed
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. (2023) pubmed
- Resmetirom: First Approval. (2024) pubmed
- Resmetirom. (2012) pubmed
- Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals. (2024) pubmed
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (2019) pubmed
- The first MASH drug therapy on the horizon: Current perspectives of resmetirom. (2024) pubmed
- Resmetirom. (2006) pubmed
- Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner. (2023) pubmed
- Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. (2024) pubmed